Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
430.00    6.00 (1.42%)
Bid:
424.50
Ask:
430.00
Spread: 5.50 (1.296%)
Market Cap: £211.48m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

22 Jan 2026 07:00

RNS Number : 8589P
Zotefoams PLC
22 January 2026
 

Zotefoams plc

("Zotefoams" or "Group")

22 January 2026

 

Full Year Trading Update

 

Ahead of market expectations, with strong revenue growth and record profitability.

 

Zotefoams, a world leader in supercritical foams, today provides a trading update for the Group's financial year ended 31 December 2025 (unaudited).

 

The Board is pleased to announce that, following a strong performance in Q4, the Group expects to report full year revenue of £158.5m (2024: £147.8m). This is slightly ahead of market expectations and represents strong year-on-year growth (+7.2%).

 

Adjusted profit before tax1 for the year is expected to be £21.1m (2024: £15.3m), up 37.9%, which is a Group record and ahead of market expectations.2

 

Year-on-year performance for the Group's three regions on a reported basis were as follows:

 

·

EMEA - 9.4% growth to £123.9m (2024: £113.3m), reflecting another exceptional year in Consumer & Lifestyle, driven by footwear revenue which benefitted from builds of new ranges and the broader footwear supply chain migration of production from China to Vietnam. The Group is finalising plans for the complex transition from manufacturing block foams in the UK to 3D midsole preforms in our new Vietnam facility that is being established through 2026 and 2027. After an extended period of strong growth, we anticipate that demand from our footwear customer will moderate in 2026 reflecting normalising inventory requirements. EMEA revenue also includes £2.0m from the recently acquired Overseas Konstellation Company S.A. ("OKC").

 

·

North America - 6.7% growth to £30.1m (2024: £28.1m) underpinned by a strong performance in Transport & Smart Technologies. Pleasingly, the Construction & Other Industrial segment saw strengthening demand in Q4, following a subdued first half of the year.

 

·

Asia revenue was £4.2m (2024: £5.1m) primarily in the Construction & Other Industrial vertical. This region will grow in importance once the Group's Vietnam footwear manufacturing facility begins operations.

 

The Group balance sheet remains strong, with significant financial headroom and a year-end leverage multiple3 expected to be at around 0.8x (2024: 0.9x), reflecting good operational cash generation and ongoing focus on working capital management, which have helped fund the strategic capital investment and the acquisition of OKC.

 

The Group has also agreed a new £90 million Multicurrency Revolving Credit Facility with £30m accordion option, on improved terms, with an enlarged syndicate that now includes, NatWest, Handelsbanken and HSBC. This facility, replacing the current £50m Multicurrency Revolving Credit Facility, will provide funding to support our strategic objectives and disciplined approach to capital allocation, including the ongoing strategic investments and selective M&A in line with our focused criteria.

 

The Group expects to publish its preliminary results for the year ended 31 December 2025 in March 2026.

 

Commenting on the update Ronan Cox, Group CEO of Zotefoams, said:

 

"In what remain challenging market conditions, we are delighted to have closed the year strongly, with good sales growth and, for a third year running, record profits ahead of market expectations.

 

The strategic progress we have made this year has been very pleasing. We were delighted to complete the acquisition of OKC, our first significant transaction under our 'Expanding Beyond the Core' strategy, which is performing well and is expected to make a meaningful contribution to the Group. Our commercial transformation into market-focused verticals continues to progress well, with our pipeline of opportunities growing across all three market verticals. Our partnership with Seoheung in Vietnam, the appointment of Brandon Thomas to lead our Asian operations, the signing of our South Korea Footwear Innovation Centre lease, and the start of work on the Global Innovation Hub at Croydon all demonstrate our commitment to positioning Zotefoams for long-term sustainable growth in line with our stated medium-term targets.

 

Our strong balance sheet and focus on cash generation with our new revolving credit facility mean we are well positioned for future strategic investment including disciplined M&A where opportunities meet our stringent criteria and align with our strategy."

 

1 Adjusted profit before tax excludes exceptional items, amortisation of acquired intangibles and other significant one-off items.

2 Zotefoams-compiled consensus expectations, for the year ending 31 December 2025, are £155.2m for net revenue and £20.5m for adjusted profit before income tax as at 22 January 2026.

3 Leverage multiple is calculated as Group net debt divided by EBITDA (before exceptional items), where Group net debt is adjusted from IFRS by the impacts of IFRS2 and IFRS16 under the bank facility definition.

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

Ronan Cox, Group CEO

Nick Wright, Group CFO

 

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

zotefoams@investor-focus.co.uk

 

 

 

About Zotefoams plc

 

Zotefoams plc (LSE - ZTF) is a world leader in supercritical fluid foam technology, delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide across three market verticals, Consumer & Lifestyle, Transport & Smart Technologies, and Construction & Other Industrial. Zotefoams uses its own materials to manufacture T-FIT® advanced insulation for demanding industrial markets.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA, Brzeg, Poland (foam manufacture), Anglesola and Burgos, Spain, and foam products conversion in Oklahoma, USA and Jiangsu Province, China (T-FIT).

 

AZOTE®, ZOTEK®, and T-FIT® are registered trademarks of Zotefoams plc.

 

www.zotefoams.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZGZMLMKGVZM
Date   Source Headline
28th Mar 20247:00 amRNSDirector/PDMR Shareholding
26th Mar 20248:36 amRNSReplacement Notice Transactions Of Directors/PDMRs
26th Mar 20247:00 amRNSGroup CEO succession
25th Mar 20245:58 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd Mar 20245:31 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSPreliminary Results
12th Mar 20241:41 pmRNSNotification Of Transactions Of Directors/PDMRs
14th Feb 20247:00 amRNSZotefoams joins independent authority, RECOUP
13th Feb 202412:31 pmRNSNotification Of Transactions Of Directors/PDMRs
7th Feb 20247:00 amRNSNotice of results and investor presentation
5th Feb 20241:20 pmRNSHolding(s) in Company
22nd Jan 20241:58 pmRNSHolding(s) in Company
18th Jan 20247:00 amRNSFull Year Trading Update
12th Jan 20245:13 pmRNSDirector/PDMR Shareholding
12th Jan 202412:28 pmRNSNotification Of Transactions Of Directors/PDMRs
5th Jan 202412:47 pmRNSReplacement Holding(s) in Company
4th Jan 20243:24 pmRNSHolding(s) in Company
4th Jan 20241:17 pmRNSHolding(s) in Company
13th Dec 20234:49 pmRNSHolding(s) in Company
13th Dec 20234:31 pmRNSReplacement Notice Transactions Of Directors/PDMRs
13th Dec 20231:54 pmRNSHolding(s) in Company
12th Dec 20233:46 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Dec 202312:45 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Dec 20231:53 pmRNSNotification Of Transactions Of Directors/PDMRs
27th Nov 20237:00 amRNSTop industry award for ReZorce® beverage cartons
14th Nov 202311:56 amRNSNotification Of Transactions Of Directors/PDMRs
8th Nov 20235:38 pmRNSHolding(s) in Company
7th Nov 20237:01 amRNSGroup CEO succession
7th Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSZotefoams programme extension at Nike
12th Oct 202312:09 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Oct 20239:47 amRNSNotification Of Transactions Of Directors/PDMRs
29th Sep 20237:00 amRNSBoard Changes
18th Sep 20234:45 pmRNSHolding(s) in Company
12th Sep 202310:57 amRNSNotification Of Transactions Of Directors/PDMRs
5th Sep 20234:07 pmRNSHolding(s) in Company
31st Aug 20233:14 pmRNSHolding(s) in Company
29th Aug 20237:00 amRNSInvestor presentation on Investor Meet Company
25th Aug 20237:00 amRNSIssue of Equity
14th Aug 20231:51 pmRNSNotification of Transactions of Directors/PDMRs
9th Aug 20233:29 pmRNSHolding(s) in Company
8th Aug 20237:00 amRNSInterim Results
19th Jul 20231:29 pmRNSHolding(s) in Company
18th Jul 20237:00 amRNSJoint development agreement for ReZorce®
12th Jul 202311:01 amRNSNotification Of Transactions Of Directors/PDMRs
10th Jul 20237:00 amRNSNotice of results and investor presentation
22nd Jun 20232:20 pmRNSHolding(s) in Company
20th Jun 202310:16 amRNSNotification Of Transactions Of Directors/PDMRs
14th Jun 20237:00 amRNSHolding(s) in Company
13th Jun 20232:55 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.